Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.

Macular sparing, optic nerve visibility predict low-risk histopathology in unilateral retinoblastoma

20 Sep 2019

Low-risk histopathologic features at primary enucleation are predicted by the presence of macular sparing, optic nerve visibility, <1 quadrant of retinal detachment (RD) or a combination thereof, which suggest safe trial eye salvage, according to a study. No clinical sign is associated with high-risk histopathologic features.

Thirty-eight eyes with vitreous seeding and normal intraocular pressure were included. The median diagnosis to enucleation interval was 4 days (range, 0–14 days). Histopathologic analysis diagnosed four (10.5 percent) high-risk and 34 (89.5 percent) low-risk eyes.

High-risk eyes were shown to have massive choroidal invasion (n=4) or trans-scleral, extraocular and postlaminar optic nerve invasion (n=1). Clinical findings were as follows: macular involvement (n=31), complete optic nerve obscuration (n=27) and RD (n=28).

Of the eyes with high-risk histopathologic features, 13 percent (4/31; 95 percent CI, 1–25 percent) had macular involvement, 15 percent (4/27; 1–28 percent) had complete optic nerve obscuration, and 14 percent (4/28; 1–27 percent) had RD.

Macular sparing (7/7; 47–100 percent), optic nerve visibility (10/10; 63–100 percent) and <1 quadrant of RD (10/10; 63–100 percent) predicted low-risk histopathologic features.

Furthermore, one child who lacked all three clinical low-risk predictive features with high-risk histopathologic features (pT3a) developed metastases and died. The other children were alive and well (mean follow-up, 65 months).

This retrospective, noncomparative, single-institutional, observational case series included children with unilateral cT2b/group D retinoblastoma managed with primary enucleation at the Hospital for Sick Children in Toronto, Canada, from January 2008 through February 2018.

The authors obtained and assessed the following data: clinical features (ie, intraocular pressure, optic nerve obscuration, macular involvement, tumour seeding and serous RD >1 quadrant), timing to enucleation, histopathologic features and follow-up.

“Attempted eye salvage for unilateral retinoblastoma may risk tumour spread compared with primary enucleation,” the investigators noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.